StemCell Therapy

Request Download Sample Ask For Discount Company Profile

New Jersey, United States,- Verified Market Reports has recently published a market research report titled, Neuropathy Pain Treatment Market Size, Status and Forecast 2021-2027. Analysts have used primary and secondary research methodologies to determine the path of the market. The data includes historic and forecast values for a well-rounded understanding. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the Neuropathy Pain Treatment market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the Neuropathy Pain Treatment market.

This report includes the assessment of various drivers, government policies, technological innovations, upcoming technologies, opportunities, market risks, restraints, market barriers, challenges, trends, competitive landscape, and segments which gives an exact picture of the growth of the Neuropathy Pain Treatment market.

Competitive analysis:

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides an in-depth analysis of the competition in the Neuropathy Pain Treatment market.

The report covers the following key players in the Neuropathy Pain Treatment Market:

Pfizer Depomed Eli Lilly Endo Grnenthal Group Arbor Pharmaceuticals

Segmentation of Neuropathy Pain Treatment Market:

The Neuropathy Pain Treatment market report has been segmented into Types, Applications, and End-users. It provides the market share of each segment participating in the Neuropathy Pain Treatment market. Companies operating in this market have a thorough understanding of the fastest-growing segment. That way, they can identify their target customers and allocate their resources wisely. Segment analysis helps create the perfect environment for engagement, customer loyalty, and acquisition. This section will help companies operating in the Neuropathy Pain Treatment market identify key areas of intervention while making their strategic investments.

By the product type, the market is primarily split into:

Calcium Channel Alpha 2-delta Ligands Serotonin-norepinephrine Reuptake Inhibitors

By the application, this report covers the following segments:

Retail Pharmacies Hospitals

Neuropathy Pain Treatment Market Report Scope

Regional analysis:

The Neuropathy Pain Treatment market report covers the analysis of various regions such as North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Market trends change by region and result in changes due to their physical environment. The report, therefore, covers key regions with sales, revenue, market share and growth rate of Neuropathy Pain Treatment in these regions from 2020 to 2027. It analyzes the region with the highest market share as well as the fastest growing region of the Neuropathy Pain Treatment market. The report by region is then broken down into analyzes at the country level. For example, North America is divided into the United States and Canada. Europe includes the UK, France, and Germany, followed by APAC, which includes countries like China, India, and Japan. Latin America is made up of countries like Mexico and Brazil, and the MEA countries included in the Neuropathy Pain Treatment market are the GCC countries and South Africa.

Research methodology:

The research methodology used to aggregate the Neuropathy Pain Treatment market report involves a combination of primary and secondary research approaches. The research team starts desk research from various sources to collect data on the Neuropathy Pain Treatment market. The report combined its data from reliable secondary sources such as company annual reports, industry publications, news, government websites and more. In addition, the primary research includes interviews to get first-hand market intelligence. Our analysts interviewed several C-level executives, decision-makers, board members, key opinion leaders, industry veterans and other stakeholders in the Neuropathy Pain Treatment market. All of the data is then combined and presented in a report to enable a deep understanding and analysis of the Neuropathy Pain Treatment market.

Why buy Neuropathy Pain Treatment Market Report?

The Neuropathy Pain Treatment market report provides a comprehensive overview of the current market and forecast till 2020-2027. It helps to identify the opportunities associated with the market in the near future. This gives our users a clear idea of ??where to use their resources. The report also includes industry dynamics such as drivers, restraints, and market opportunities that are significantly influencing the growth of the Neuropathy Pain Treatment market. In-depth study of general market expansion that helps users make product launch and asset development decisions. The report covers recent developments and changing market trends with the aim of making the appropriate decisions.

Visualize Neuropathy Pain Treatment Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment and Key players of your market. Present your Market Report & findings with inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyse data on more than 25,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website: https://www.verifiedmarketreports.com/

View post:
Neuropathy Pain Treatment Market Size | Latest COVID19 Impact Analysis | Demand, Growth, Trends, Segmentation and Forecasts to 2027 - NeighborWebSJ

Global Neuropathy Pain Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025 presents a point of view for the existing market trends, metrics, drivers, and restrictions, and all the important segments. The report specializes in an in-depth study of the global Neuropathy Pain Treatment market with a focus on the global market trend. The report is suitably segmented and sub-segmented so that it can shed light on every aspect of the market such as type of product, application, and region. The research contains key statistics on the market status of the leading market players and offers key trends and opportunities in the market. The report prophesies future revenue, growth, and trend of the market on the basis of recent developments and past data. Then the research emphasizes faster-growing segments and emerging trends in the market.

The report has extracted a systematic analysis of actual and projected market data. Key points covered are Drivers, restraints, opportunities, market revenue, trends shares, vendor profiling, manufacturers or players. The report layouts the global Neuropathy Pain Treatment market segments by defining and evaluating them, and forecast the global market size. The report identifies various developments, broad opportunities, and market growth factors. The study covers current status, market share, future patterns, development rate, SWOT examination, sales channels, to anticipate growth scenarios for the years 2020-2025. It aims to recommend analysis of the market with regards to growth trends, prospects, and players contribution in the market development.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/9018

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Exploring Growth Rate Over A Period:

This report contains data regarding the rise in sales within a given consumer base for the forecast period, 2020 to 2025. With this precisely documented report, business owners can scale up their business. Product owners can use this information along with the driving factors such as demographics and revenue generated from other products discussed in the report to get a better analysis of their products and services. Besides, the research analysts have compared the global Neuropathy Pain Treatment market growth rate with the product sales to assist business owners to determine the success or failure of a specific product or service.

Leading companies covered in this research report: Pfizer, Endo, Depomed, Eli Lilly, Arbor Pharmaceuticals, Grnenthal Group

Market segmentation by product types: Calcium Channel Alpha 2-delta Ligands, Serotonin-norepinephrine Reuptake Inhibitors, Others

Market segmentation by applications: Retail Pharmacies, Hospitals, Others

Key regions and countries covered in this research report: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey and South Africa)

ACCESS FULL REPORT: https://www.marketquest.biz/report/9018/global-neuropathy-pain-treatment-market-2020-by-company-regions-type-and-application-forecast-to-2025

Reasons To Buy A Full Report:

Moreover, the report will help the industry players in deciding the investment feasibility and development status across the globe. The analysis of global Neuropathy Pain Treatment market share, revenue, pricing analysis, SWOT analysis is covered for all the key market players. All the product segments and sub-segments are studied in detail in this report.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketquest.bizWeb: http://www.marketquest.biz

Go here to read the rest:
Global Neuropathy Pain Treatment Market 2020 2025 Business Statistics of Report that Emphasizes the impact of COVID-19 FLA News - FLA News

According to the new market research report Neuropathy Pain Treatment Market Strategic recommendations, Trends, Segmentation, Use Case Analysis, Competitive Intelligence, Global and Regional Forecast (to 2026), published by In4Research, the global Neuropathy Pain Treatment Market size in the post-COVID-19 scenario is projected to grow significantly by 2026.

Study Objectives of Global Neuropathy Pain Treatment Market:

Request for a sample copy of the report to get extensive insights into Neuropathy Pain Treatment market at https://www.in4research.com/sample-request/53942

Research Coverage of Neuropathy Pain Treatment Market:

The market study covers the Neuropathy Pain Treatment market size across different segments. It aims at estimating the market size and the growth potential across different segments, including application, type, organization size, vertical, and region. The study further includes an in-depth competitive analysis of the leading market players, along with their company profiles, key observations related to product and business offerings, recent developments, and market strategies.

Major Key Players Covered in The Neuropathy Pain Treatment Market Report include

Neuropathy Pain Treatment Market Segmentation by Type, Application, and Region as follows:

By Type:

By Application:

Geographically, this report is segmented into several key Regions along with their respective countries, with production, consumption, revenue, and market share and growth rate of Neuropathy Pain Treatment in the following regions:

For more Customization, Connect with us at https://www.in4research.com/customization/53942

Valuable Points Covered in Neuropathy Pain Treatment Research Study are:

Moreover, the analyst who has authored the report has completely estimated the market potential of the key applications and recognized the future opportunities. The top players in the global Neuropathy Pain Treatment market are covered based on their market size, served market, products, applications, and regional growth. The report comprises the industry deliverables such as market size, sales volume, valuation forecast, etc. The report focuses on the upstream raw material analysis, downstream analysis, manufacturing base, and import-export details.

Any Questions/Queries or need help? Speak with our analyst https://www.in4research.com/speak-to-analyst/53942

Key Topics Covered in Neuropathy Pain Treatment Research Study are:

Introduction

Value Chain Analysis

Porters Five Forces Analysis

Pricing Analysis

And more

Buy Full Research Report at https://www.in4research.com/buy-now/53942

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan

Email: [emailprotected]

Phone: +1 (407) 768-2028

https://neighborwebsj.com/

Read the original post:
Recent Study on Neuropathy Pain Treatment Market 2021 Including Key Players, Applications, and Growth Size By 2026 NeighborWebSJ - NeighborWebSJ

Market Study Report, LLC, has recently added a report on ' Diabetic Neuropathy market' which offers a comprehensive synopsis of revolving market valuation, market size, SWOT analysis, revenue estimation and geographical spectrum of the market. The report further elucidates primary business obstacles and growth prospects within the forecasted timeline, while examining the current competitive sphere involving key players of the ' Diabetic Neuropathy market'.

The research analysis of Diabetic Neuropathy market provides a broad perspective of the major development trends, limitations, and restraints as well as growth opportunities, which are slated to define the industry growth rate in the subsequent years.

Request a sample Report of Diabetic Neuropathy Market at:https://www.marketstudyreport.com/request-a-sample/3171246?utm_source=Algosonline.com&utm_medium=Ram

According to the report, the Diabetic Neuropathy market is predicted to witness a y-o-y growth rate during the analysis timeframe (2021-2026) and generate lucrative returns by the end of the forecast duration.

The advent of COVID-19 pandemic is expected to have some modifications to the growth of this business vertical. Various organizations operating in this industry landscape are compelled to revisit their respective budgets in order to establish a proper profit trajectory for the ensuing years. Thus, the study offers an in-depth analysis regarding the impact of the COVID-19 pandemic on the overall industry remuneration.

Apart from this, the document also highlights the various segmentations and their individual contribution towards the overall market outlook.

Major information from the Diabetic Neuropathy market report:

Ask for Discount on Diabetic Neuropathy Market Report at:https://www.marketstudyreport.com/check-for-discount/3171246?utm_source=Algosonline.com&utm_medium=Ram

Diabetic Neuropathy Market segments covered in the report:

Regional segmentation: North America, Europe, Asia-Pacific, South America, Middle East and Africa

Product types:

Applications spectrum:

Competitive outlook:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-diabetic-neuropathy-market-2021-by-company-regions-type-and-application-forecast-to-2026

Key Highlights Questions?

Table of Content:

Read More Reports On: https://www.marketwatch.com/press-release/monodose-packaging-for-probiotics-and-nutraceutical-market-share-growth-statistics-by-application-production-revenue-forecast-to-2026-2021-02-05

Contact Us:Corporate Sales,Market Study Report LLCPhone:1-302-273-0910Toll Free:1-866-764-2150Email:[emailprotected]

Read more from the original source:
Diabetic Neuropathy Market Outlook, Strategies, Manufacturers, Countries, Type and Application, Global Forecast To 2026 - AlgosOnline

Pipeline strategies by manufacturers are focused on introducing advanced drugs with minimum side effects to increase market share. For instance, Pfizer sponsored drug Pregabalin, effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma that is in phase 3 clinical trials. Increasing research and development activities to develop medications for indications such as post-herpetic neuralgia are creating significant opportunities for manufactures to flourish in the market.

Reaching the revenues of overUS$ 6 Bnat the end of 2019, the globalneuropathic pain management marketis projected for a healthy CAGR during the forecast period (2019 2029). Increasing prevalence of neuropathic pain disorders and growing awareness about pain medication are boosting the demand for pain management drugs.

Want a sneak peek into the Neuropathic Pain Market? Access the Table of Content of Neuropathic Pain Market report! @https://www.persistencemarketresearch.com/market-research/neuropathic-pain-market/toc

Pipeline strategies by manufacturers are focused on introducing advanced drugs with minimum side effects to increase market share. For instance, Pfizer sponsored drug Pregabalin, effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma that is in phase 3 clinical trials. Increasing research and development activities to develop medications for indications such as post-herpetic neuralgia are creating significant opportunities for manufactures to flourish in the market.

Get going with a sample of Neuropathic Pain Market report!@https://www.persistencemarketresearch.com/samples/4149

Company Profiles

Key Takeaways Neuropathic Pain Management Market Study

Increasing prevalence of diabetic neuropathy and availability of approved neuropathy pain medications have significantly added to the opportunities for market growth, thereby fostering the rate of adoption of neuropathic pain management drugs.

Increasing R&D Spending by Pharmaceuticals Companies Shaping Future

One of the key factors observed to impact the neuropathic pain management market growth is the development of new drugs for treatment of neuropathic and chronic pains. Companies are focusing on clinical trials to develop drugs for efficient treatment of neuropathic pain. For instance, Eli Lilly and Company developed Duloxetine (LY248686) for Diabetic Peripheral Neuropathic Pain (DPNP) that is under phase 4 clinical trial.

At the same time, companies are focused on expanding therapeutic applications of drugs such as opioids and steroids for neuropathic pain management without causing any serious side effects to patients. Currently, more than 100 clinical trials are been carried out for pain management. Among those clinical trials, nearly half of the clinical trials are for various indications of neuropathic pain such as diabetic neuropathy and post-herpetic neuralgia.

What Does the Report Cover?

The neuropathic pain management market, a new study from Persistence Market Research, provides unparalleled insights on evolution of the neuropathic pain management market during 2014 2018 and presents demand projections during 2019 2029 on the basis of drug class (tricyclic anti-depressants, anticonvulsants, SNRIs, capsaicin cream, local anesthesia, opioids, steroids, and others), indication (diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others), distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies) across prominent regions (North America, Latin America, Europe, Asia Pacific and MEA).

About UsPersistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping business ride high, irrespective of the turbulence faced on the account of financial/natural crunches.Contact Us:Persistence Market Research (PMR)Address 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales sales@persistencemarketresearch.com

See original here:
North America to Stand in a Better Stead in the Neuropathic Pain Market between 2020 and 2030 - Industry Today

Diabetes is a common condition that affects around five million people in the UK. But a lot of people may not even know that they have diabetes. You could be at risk if you develop a subtle pain in your legs.

Diabetes is a life-long condition, and 90 percent of all cases are caused by type 2 diabetes.

Type 2 diabetes is where the body struggles to produce enough of the hormone insulin.

Insulin helps the body to convert sugar in the blood into useable energy.

But if your body isn't getting enough insulin, the amount of sugar in your blood starts to rise, which can lead to diabetes.

READ MORE: Type 2 diabetes symptoms - 'dark adaption' could be a warning sign

"Diabetic neuropathy is a type of nerve damage that can occur if you have diabetes," said the Mayo Clinic.

"High blood sugar can injure nerves throughout your body. Diabetic neuropathy most often damages nerves in your legs and feet.

"Depending on the affected nerves, diabetic neuropathy symptoms can range from pain and numbness in your legs and feet to problems with your digestive system, urinary tract, blood vessels and heart.

"Some people have mild symptoms. But for others, diabetic neuropathy can be quite painful and disabling."

Meanwhile, other common symptoms of diabetes include passing more urine than normal, and feeling unusually tired.

Some people also find that they're always feeling thirsty, despite drinking plenty of fluids.

Speak to a doctor if you're worried about the signs of diabetes.

Diagnosing the condition early could help to lower your risk of diabetes complications, including strokes or heart disease.

Read more from the original source:
Diabetes symptoms: Sign in your legs of high blood sugar - the 'pain' you shouldn't ignore - Express

DUBLIN, Ireland, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today reported financial results for the fourth quarter and full year 2020. In addition, the Company provided 2021 financial guidance and an update on its R&D programs.

We continue to see positive momentum in our pipeline with the recent announcement of the confirmatory, registration-enabling Phase 3 AFFIRM-AL study of birtamimab in AL amyloidosis and positive clinical findings reported in 2020 from both the Phase 2 study of prasinezumab in Parkinsons disease and Phase 1 study of PRX004 in ATTR amyloidosis, said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena. We are particularly pleased that our unique protein dysregulation platform has now resulted in the translation of our preclinical findings into clinical benefit for patients across multiple programs in our portfolio. We look forward to a number of significant milestones in 2021, with the planned initiation of 3 late-stage clinical studies, including the birtamimab AFFIRM-AL study, the prasinezumab Phase 2b study and the PRX004 Phase 2/3 study. In addition to these late-stage programs, we have also advanced the three targets under our global neuroscience collaboration with Bristol-Myers Squibb and expect to file an IND for PRX005 this year. Our strong cash position and potential partner payments provide a foundational capital position to fund the company through value-creating milestones as we transition to a fully integrated commercial company.

Story continues

Full Year 2020 and Recent Developments:

Birtamimab, a potential treatment for AL amyloidosis, is a humanized monoclonal antibody designed to directly neutralize soluble toxic aggregates and promote clearance of amyloid that causes organ dysfunction and failure

Based on significant survival benefit observed in the previous VITAL study in Mayo Stage IV patients (HR=0.413, p=0.025, over 9 months) and multiple in-depth discussions with the U.S. Food and Drug Administration (FDA), Prothena announced plans in February 2021 to advance birtamimab into the confirmatory Phase 3 AFFIRM-AL study in Mayo Stage IV patients with AL amyloidosis. AFFIRM-AL is a global, registration-enabling Phase 3 study that will be conducted with a primary endpoint of all-cause mortality at p0.10 under a Special Protocol Assessment (SPA) agreement with FDA.

Prasinezumab, a potential treatment for Parkinsons disease, is a humanized monoclonal antibody designed to target key epitopes within the C-terminus of alpha-synuclein and is the focus of the worldwide collaboration with Roche

Presented results from Phase 2 PASADENA study showing prasinezumab significantly slows progression on pre-specified clinical measures of Parkinsons disease in September 2020 at the International Parkinson and Movement Disorder Societys 2020 Congress. Prasinezumab is the first potentially disease-modifying, anti-alpha-synuclein antibody to demonstrate signals of efficacy on multiple pre-specified secondary and exploratory clinical endpoints in patients with early Parkinsons disease.

Announced that Roche and Prothena will advance prasinezumab into a late-stage Phase 2b study in patients with early Parkinsons disease. The study will be designed to further assess the efficacy of prasinezumab by expanding upon the patient population enrolled in PASADENA to include patients with early Parkinsons disease on stable levodopa therapy. Prasinezumab is the first anti-alpha synuclein antibody to advance into late-stage development.

PRX004, a potential treatment for ATTR amyloidosis, is a humanized monoclonal antibody designed to deplete the pathogenic, non-native forms of the TTR protein

Reported results from the Phase 1 study of PRX004, the first anti-amyloid immunotherapy designed to deplete amyloid to demonstrate efficacy in ATTR amyloidosis. In the first report of clinical results with this depleter mechanism of action, PRX004 showed favorable results as demonstrated by slowing of neuropathy progression for all 7 evaluable patients at 9 months, including improvement in neuropathy in 3 of the 7 patients, and improved cardiac systolic function for all 7 patients. In this Phase 1 study, PRX004 was found to be generally safe and well tolerated across all dose levels.

PRX012, a potential treatment for Alzheimers disease, is monoclonal antibody targeting key epitopes within the N-terminus of A

Multi-immunogen vaccine, for the potential prevention and treatment of Alzheimers disease, is a multi-immunogen A-tau vaccine

Presented data on a multi-immunogen vaccine that targets key A and tau epitopes, the two main pathological proteins involved in the cause and progression of Alzheimers disease, at the CTAD Conference in November 2020

Corporate

Appointed Brandon Smith as Chief Business Officer, responsible for leading Prothenas business development activities, portfolio strategic planning and alliance management activities. Mr. Smith joined Prothena after serving as Chief Operating Officer at Iconic Therapeutics

Upcoming Milestones:

Birtamimab

Prasinezumab

New pre-specified exploratory subgroup analyses from Part 1 of the Phase 2 PASADENA study to be presented at the 15th International Conference for Alzheimers and Parkinsons Diseases in March 2021 (ADPD 2021)

$60 million clinical milestone payment to be achieved upon first patient dosed in late-stage Phase 2b study in patients with early Parkinsons disease; further details expected in 2Q 2021

Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference

PRX004

PRX005

Preclinical data to be presented in March at ADPD 2021

IND filing expected 3Q 2021

$80 million potential payment from Bristol-Myers Squibb upon exercising their US license option in 2021

PRX012

Upcoming Investor Conferences

Members of the senior management team will present and participate in investor meetings at the following upcoming investor conferences:

H.C. Wainwright Global Life Sciences Conference on Tuesday and Wednesday, March 9-10, 2021, virtual presentations will be available on demand both days

Oppenheimer 31st Annual Healthcare Conference on Wednesday March 17, 2021 at 10:00 AM ET

Stifels 3rd Annual CNS Day on Thursday April 1, 2021 at 8:00 AM ET

Fourth Quarter and Full Year of 2020 Financial Results and 2021 Financial Guidance

For the fourth quarter and full year of 2020, Prothena reported a net loss of $30.7 million and $111.1 million, respectively, as compared to a net loss of $21.6 million and $77.7 million for the fourth quarter and full year of 2019, respectively. Net loss per share for the fourth quarter and full year of 2020 was $0.77 and $2.78, respectively, as compared to a net loss per share of $0.54 and $1.95 for the fourth quarter and full year of 2019, respectively.

Prothena reported total revenue of $0.4 million and $0.9 million for the fourth quarter and full year of 2020, respectively, primarily due to license revenue in the fourth quarter and collaboration revenue for the full year as compared to total revenue of $0.3 million and $0.8 million for the fourth quarter and full year of 2019, respectively, primarily due to Roche collaboration revenue.

Research and development (R&D) expenses totaled $20.8 million and $74.9 million for the fourth quarter and full year of 2020, respectively, as compared to $15.5 million and $50.8 million for the fourth quarter and full year of 2019, respectively. The increase in R&D expense for the fourth quarter and full year of 2020 compared to the same periods in the prior year was primarily due to higher manufacturing costs primarily related to our PRX005, birtamimab and PRX012 programs and to a lesser extent PRX004, higher collaboration expense with Roche related to the prasinezumab program and higher R&D consulting expense. R&D expenses included non-cash share-based compensation expense of $2.1 million and $8.2 million for the fourth quarter and full year of 2020, respectively, as compared to $2.0 million and $8.1 million for the fourth quarter and full year of 2019, respectively.

General and administrative (G&A) expenses totaled $9.9 million and $38.7 million for the fourth quarter and full year of 2020, respectively, as compared to $8.1 million and $35.7 million for the fourth quarter and full year of 2019, respectively. The increase in G&A expenses for the fourth quarter and full year of 2020 compared to the same periods in the prior year was primarily related to higher costs for our director and officer insurance premiums. G&A expenses included non-cash share-based compensation expense of $3.2 million and $13.8 million for the fourth quarter and full year of 2020, respectively, as compared to $3.3 million and $15.5 million for the fourth quarter and full year of 2019, respectively.

Total non-cash share-based compensation expense was $5.2 million and $22.0 million for the fourth quarter and full year of 2020, respectively, as compared to $5.3 million and $23.6 million for the fourth quarter and full year of 2019, respectively.

As of December 31, 2020, Prothena had $298.1 million in cash, cash equivalents and restricted cash and no debt.

As of February 5, 2021, Prothena had approximately 39.9 million ordinary shares outstanding.

The Company expects the full year 2021 net cash used in operating and investing activities to be $51 to $74 million, which includes an expected $60 million milestone payment from Roche upon first patient dosed in the late-stage Phase 2b study of prasinezumab and expects to end the year with approximately $235 million in cash, cash equivalents and restricted cash (midpoint). The estimated full year 2021 net cash used in operating and investing activities is primarily driven by an estimated net loss of $79 to $111 million, which includes an estimated $20 million of non-cash share-based compensation expense.

Conference Call Details

Prothena management will discuss these results and its 2021 financial guidance during a live audio conference call today, Thursday, February 11, 2021, at 8:30 AM ET. The conference call will be made available on the Company's website at http://www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days.

To access the call via dial-in, please dial (877) 887-5215 (U.S. and Canada toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 5677514. A replay of the call will be available until February 25, 2021 via dial-in at (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 5677514.

About Prothena

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a pipeline of novel investigational therapeutics with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothenas pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimers disease, Parkinsons disease and a number of other neurodegenerative diseases. For more information, please visit the Companys website at http://www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Forward-looking Statements

This press release contains forward-looking statements. These statements relate to, among other things, the sufficiency of our cash position to fund advancement of a broad pipeline; our goal of building a protein dysregulation platform; the treatment potential and proposed mechanisms of action of birtamimab, prasinezumab, PRX004, PRX005, PRX012, and multi-immunogen A-tau vaccine; plans for future clinical studies of birtamimab, prasinezumab, PRX004, PRX005, and PRX012; amounts we might receive under our collaborations with Roche and Bristol-Myers Squibb; the expected timing of reporting data from prior clinical studies of birtamimab, the Phase 2 clinical study of prasinezumab, and preclinical studies of PRX005; our anticipated net cash burn from operating and investing activities for 2021 and expected cash balance at the end of 2021; and our estimated net loss and non-cash share-based compensation expense for 2021. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to the effects on our business of the worldwide COVID-19 pandemic and the risks, uncertainties and other factors described in the Risk Factors sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2020, discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC, and our Annual Report on Form 10-K to be filed with the SEC for our fiscal year 2020. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.

PROTHENA CORPORATION PLCCONSOLIDATED STATEMENTS OF OPERATIONS(unaudited - amounts in thousands except per share data)

Three Months EndedDecember 31,

Twelve Months EndedDecember 31,

2020

2019

2020

2019

Collaboration revenue

$

121

$

256

$

564

$

814

License revenue

239

289

Total revenue

360

256

853

814

Operating expenses:

Research and development

20,760

15,471

74,884

50,836

General and administrative

9,908

8,059

38,703

35,736

Restructuring (credits)

(61

)

Total operating expenses

30,668

23,530

113,587

86,511

Loss from operations

(30,308

)

Read more from the original source:
Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update - Yahoo Finance

Diabetic Foot Ulcer Therapeutics Market is valued at USD 2549.3 Million in 2018 and expected to reach USD 4397.4 Million by 2025 with a CAGR of 8.1% over the forecast period. Increasing geriatric population across the globe is anticipated to drive growth of Global Diabetic Foot Ulcer Therapeutics Market.

Diabetic foot ulcers are a common complication of poorly controlled diabetes, forming as a result of skin tissue breaking down and exposing the layers underneathThere is a more possibility that people with diabetes can develop foot ulcers but good foot care can help prevent them. Theyre most common under the big toes and the balls of feet, and they can affect the feet down to the bones. The risk of developing a diabetic foot ulcer increases with in time. The major causes of diabetic ulcers includes; poor circulation, high blood sugar, nerve damage and irritated or wounded feet. A majority of non-infected foot ulcers are treated without surgery; however, if this treatment fails, surgical management may be appropriate. Major surgical procedures to remove the pressure on affected area majorly include the correction of various deformities such as hammertoes, bunions, or bony bumps and shaving or excision of bone. Healing time depends on a variety of factors which includes; wound size and location, pressure on the wound from walking or standing, blood glucose levels, swelling, circulation, wound care and others. Healing may require few weeks or several months. The top priority in treating the diabetic foot syndrome is to avoid a major amputation.

Get Sample Copy of The Report@https://brandessenceresearch.com/requestSample/PostId/308

Global diabetic foot ulcer therapeutics market report is segmented on the basis of product type, ulcer type, end-user and region & country level. Based upon product type, global diabetic foot ulcer therapeutics market is classified into wound care dressings, therapy devices, biologics, antibiotic medications and others. Based upon ulcer type, global diabetic foot ulcer therapeutics market is divided into neuropathic ulcers, neuro-ischemic ulcers and ischemic ulcers. Based on end-user, the diabetic foot ulcer therapeutics market is classified into hospitals, ambulatory surgical center, specialty clinics and others.

The regions covered in this Global Diabetic Foot Ulcer Therapeutics Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of diabetic foot ulcer therapeutics is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.

Some major key players for global diabetic foot ulcer therapeutics market are Acelity L.P. Inc., 3M Healthcare, ConvaTec, Inc., Medline Industries, Inc., Medtronic Plc., Coloplast A/S, Smith & Nephew Plc., B. Braun Melsungen AG, Molnlycke Health Care AB, Organogenesis, Inc., BSN Medical GMBH and others.

Increasing Geriatric Population Coupled with the Increasing Prevalence of Diabetes Worldwide Drives Global Diabetic Foot Ulcer Therapeutics Market

The major factor driving the growth of global diabetic foot ulcer therapeutics market is increasing incidences of foot ulcers coupled with the increasing prevalence of diabetes. For example; As per National Center for Biotechnology Information; The prevalence of diabetic foot ulcer among diabetic patients in Gondar University Referral Hospital was found to be high. Residence, higher BMI (overweight and obesity), types of diabetes, neuropathy, and foot self-care practice were factors significantly associated with diabetic foot ulcer. In addition, increasing inclination towards the avoidance of surgeries and amputation is also supplementing the growth of diabetic foot ulcer market. Furthermore, increasing geriatric population is also fostering the market growth as this population is more prone to diabetes. However, high cost of ulcer treatments may hamper the market growth. In spite of that, increasing advancements in and adoption of innovative ways of treatments can provide various opportunities for the further growth of the market.

North America is Expected to Dominate the Global Diabetic Foot Ulcer Therapeutics Market

The global diabetic foot ulcer therapeutics market is segmented into North America, Europe, Asia-Pacific Latin America and Middle East & Africa. North America is expected to dominate the global diabetic foot ulcer therapeutics market within the forecast period attributed to large diabetic patient pool due to the an aging population and the growth of minority populations are expected to add to the diseases prevalence. For example; Centers for Disease Control and Prevention; In the United States, Currently, 1 in 10 Americans has Type 2 diabetes and if current trends continue then 1 in 3 people will have Type 2 diabetes by 2050. But if new cases develop as estimated then its prevalence could double or triple over the next 40 years. In addition, highly developed healthcare infrastructure and increasing adoption of wound care devices are also supplementing the growth of diabetic foot ulcer therapeutics market in this region.

Asia Pacific is anticipated to witness a lucrative growth in global diabetic foot ulcer therapeutics market owing to the increasing geriatric population which is more prone to diabetes. The aging of the population in China and India will bring with it an increase in the burden of chronic disease. The number of people with diabetes in China is projected to increase 103.4 percent, from 20.8 million to 42.3 million, between 2000 and 2030. In comparison, the rate of diabetes in India is expected to increase 150.5 percent, from 31.7 million to 79.4 million, over the same period.

Get Methodology of Report @https://brandessenceresearch.com/requestMethodology/PostId/308

Key Benefits Market Report

Market Segmentation:-

By Product Type:

By Ulcer Type:

By End-User:

By Regional & Country Level:

Get Full Report :@https://brandessenceresearch.com/healthcare/diabetic-foot-ulcer-therapeutics-market-size

View post:
Diabetic Foot Ulcer Therapeutics Market Overview 2021: Top Companies Analysis, Outlook, Market Share, Trends and Segmentation KSU | The Sentinel...

Pain is a common cancer symptom. In fact, its estimated that approximately 66 percent of people with cancer will experience pain as a symptom at some point.

Cancer pain can have several causes. These can include the cancer itself or the effects of various treatments or surgeries that are used to treat the cancer.

While all cancers can cause pain, some, such as those affecting the bones or pancreas, are more frequently associated with pain. Regardless of the type of cancer, its important that remember that cancer pain can often be treated.

Continue reading below to learn more about cancer and pain, how this pain can be managed, and more.

All cancers have the potential to cause pain. The amount of cancer pain you may experience can depend on many different factors, including:

According to the National Cancer Institute, younger individuals are more likely to experience cancer pain and people with advanced cancer tend to experience more severe pain.

When the cancer itself causes pain, its often due to a tumor thats pressing on other organs, bones, or nerves. Tumors can also spread to other areas, such as the spinal cord and bones, leading to pain as well.

Below, well discuss some types of cancer that are commonly associated with pain and why the pain may occur. As we do so, its important to keep in mind that even severe cancer pain can be treated.

Bone cancer is when cancer occurs in your bones. Cancer that originates in the bone, which is called primary bone cancer, is actually quite rare in adults. In fact, it makes up only 0.2 percent of all cancers.

Many times, when someone has bone cancer, its actually due to cancer thats spread to the bones from another location in the body. This can happen with many types of cancer, such as those of the breast, lung, and prostate.

Pain is one of the main symptoms of cancer in the bones. The presence of cancer cells can interfere with the normal maintenance of bone tissue, making your bones weaker. A growing tumor may also press on nerves around the bone.

The pain from bone cancer often begins as a dull pain that comes and goes and is typically worse at night. Eventually, the pain can become constant. Because bone tissue has become weak, its also prone to breaking.

Pancreatic cancer is cancer that develops in your pancreas. The pancreas is an organ that produces enzymes that are important for digestion. It also helps to regulate your blood sugar.

In its early stages, pancreatic cancer can be asymptomatic. Because of this, about 80 percent of pancreatic tumors are detected at more advanced stages. When symptoms are present, they can include abdominal or back pain, jaundice, and weight loss.

Pain from pancreatic cancer can be severe. It can be due to a tumor that presses on surrounding nerves, the spine, or organs in your abdomen like your liver or intestines.

Head and neck cancers are those that start in your:

The symptoms of head and neck cancer can depend on their specific location but often include pain. Like other types of cancer, pain is often due to a tumor that presses on surrounding nerves and structures.

Cancer pain can be exacerbated in the head and neck because the area has a high number of nerves. Additionally, your head and neck contain many structures that are situated within a relatively small space.

A tumor in your head or neck can also cause discomfort by interfering with various body functions. These can include things like eating, swallowing, or breathing.

Your brain and spinal cord make up your central nervous system (CNS). The CNS collects, processes, and responds to sensory information collected from your body and your environment. Think of it as your bodys control center.

Tumors around your brain or spinal cord can put pressure on the surrounding nerves and structures, leading to pain. This can also cause other symptoms like seizures, trouble with movement, and sensory problems.

The most common symptom of a brain tumor in adults is headache. These headaches often become more frequent and severe as time passes.

Pain from a tumor affecting the spinal cord can be characterized as burning, sharp, or tingling. It can happen at a specific location and may also radiate out to other areas of the body. It can be severe and may become constant as time passes.

Lung cancer is cancer that starts in your lungs. Its one of the most common cancers in the world.

Similar to pancreatic cancer, lung cancer has few symptoms in its early stages. Because of this, many times it isnt diagnosed until more advanced stages.

As lung cancer grows and spreads, it can put pressure on your lungs and chest wall. This can lead to chest pain that gets worse when you breathe, cough, or laugh.

Additionally, tumors may partially or completely block some airways. This can also lead to discomfort and can cause distressing symptoms like shortness of breath and wheezing.

There are many different ways to help manage cancer pain. Lets take a deeper dive into some of them below.

Many times, medications are prescribed to help ease cancer pain. Your doctor will select a medication based on whether your pain levels are mild, moderate, or severe.

Some examples of medications that can be given for cancer pain are:

In addition to medications, there are other ways to help manage cancer pain. These can include:

In addition to pain thats caused from the cancer itself, the various types of cancer treatments can also potentially lead to pain. Lets explore this further.

Surgery may be used to remove a tumor from your body. If you have surgery for cancer, its normal to experience postoperative pain in the days or weeks after your procedure.

Pain from surgery is typically treated using medications. Its possible youll need to use stronger pain medications right after your surgery and then switch to less strong medications in the following days.

In some cases, you may experience phantom pain following surgery. This is pain or discomfort that feels like its coming from an area of your body thats been removed. It may happen if youve had a breast or limb surgically removed.

There are several treatment methods that may work for phantom pain. These include medications, TENS, or physical therapy.

Chemotherapy uses strong medications to kill cancer cells. However, it can also lead to side effects that can be painful. One of these is chemotherapy-induced peripheral neuropathy (CIPN), which can cause pain, numbness, and tingling.

According to the National Cancer Institute, studies on medications and natural products to help relieve pain due to CIPN have had mixed results. Some examples of medications that may be used include:

Alterative treatment methods for CIPN are also being explored. Some examples of these include acupuncture and relaxation therapy.

Mouth and throat sores may also develop as a side effect of chemotherapy. While these often go away on their own eventually, you can ease discomfort by applying a topical pain medication and avoiding foods that may irritate the sores.

Radiation therapy utilizes high amounts of radiation to kill cancer cells. Like chemotherapy, it may also cause painful side effects. These can include:

Treatment for the side effects of radiation therapy can depend on the symptoms youre experiencing. They may include pain medications, steroids for inflammation, or antiseizure medications for nerve pain.

Other types of cancer treatments, such as immunotherapy and targeted therapy may cause pain as a side effect as well.

Medications are used to help ease these side effects as you receive treatment. Side effects typically go away once your treatment ends.

Cancer pain can be effectively managed using a variety of methods, helping to ease this symptom and improve your quality of life. Because of this, talk with your doctor if you have cancer and experience pain that:

When you see your doctor, be sure to tell them:

Its likely that youll be asked to rate your pain on a scale. For example, this may be done on scale of 1 to 10, where 1 would mean that youre experiencing little pain and 10 would mean that youre experiencing very severe pain.

Your doctor and care team can use this information as well as your medical history to help develop a plan to better manage your pain.

If youve recently been diagnosed with cancer, you may feel scared or worried. There are resources that can help you to cope with these feelings.

One of these resources is support groups. Support groups are made up of people whose lives have been touched by cancer. These can include other people with cancer, their loved ones, and cancer survivors.

In these groups, you can discuss your experience with cancer, learn about new treatments, and receive support and encouragement from others. Some resources for finding a support group near you are:

Its also possible that you may not be ready to talk about your feelings in a group setting. This is completely normal.

If youre feeling distressed, anxious, or depressed about your diagnosis, it may be beneficial to speak to a mental health professional like a psychologist or psychiatrist. Your doctor can recommend one near you that has experience working with people with cancer.

Pain is a common symptom of cancer. It can be caused by the cancer itself, by the methods used to treat cancer, or both.

Some cancers are associated with more pain than others. These can include those of the bones, pancreas, and head and neck. However, pain can happen with all cancers.

Its always important to keep in mind that cancer pain is treatable. In fact, there are many methods that may be used to manage cancer pain.

Speak to your doctor if you have new pain, pain that doesnt go away, or pain that happens even when you take your current pain medications. They can work with you to adjust your pain management plan to help alleviate cancer pain.

Read this article:
Most Painful Cancer: What to Know about Pain and Treatment - Healthline

Blood sugar - the main type of sugar you get from eating food - supplies the body's cells with energy. However, consistently high levels can unleash destruction on the body. If you have type 2 diabetes, you are prone to high blood sugar levels because the main regulating force - insulin production - is impaired.

The effects of high blood sugar levels often constitute the first perceptible warning signs of type 2 diabetes.

Some of the most acute symptoms stem from autonomic neuropathy - damage to nerves that control your internal organs.

As the National Institute of Diabetes and Digestive and Kidney Diseases (NIH), high blood sugar in the blood from diabetes can damage your nerves and the small blood vessels that nourish your nerves, leading to autonomic neuropathy.

Struggling to adjust your eyes in a dark room is a warning sign of autonomic neuropathy.

READ MORE:Diabetes type 2 symptoms: The alternating toilet habits that signal high blood sugar

NIH explains: "Damage to the nerves in your pupils may make them slow to respond to changes in light and darkness."

The health body adds: "Your eyes may take longer to adjust when you enter a dark room. You may have trouble seeing the lights of other cars when driving at night."

This is otherwise known as 'dark adaptation', which refers to how the eye recovers its sensitivity in the dark after exposure to bright lights

Other signs of autonomic neuropathy include problems with:

DON'T MISSCoronavirus new strain symptoms: The 12 symptoms[INSIGHT]Coronavirus new strain symptoms: Seven new symptoms[ADVICE]Apple cider vinegar recipe: How to drink[TIPS]

According to the NHS, you should see a GP if you have any of the symptoms of type 2 diabetes or you're worried you may have a higher risk of getting type 2 diabetes.

"You'll need a blood test, which you may have to go to your local health centre for if it cannot be done at your GP surgery."

The earlier diabetes is diagnosed and treatment started, the better.

As the NHS explains, early treatment reduces your risk of other health problems.

Lifestyle changes are usually recommended to bring blood sugar levels down to keep the risks of diabetes at bay.

There are two key components to blood sugar control - eating a healthy, balanced diet and regular exercise.

A common misconception about type 2 diabetes is that you need to avoid eating certain foods.

There's technically nothing you cannot eat if you have type 2 diabetes, but you'll have to limit certain foods.

The worst offenders are carbohydrates because carbs are brown down into glucose relatively quickly - this causes spikes in blood sugar.

There are some general dietary principles that can help you to manage type 2 diabetes.

According to the NHS, you should:

Physical exercise helps lower your blood sugar level - you should aim for 2.5 hours of activity a week, advises the health body.

"You can be active anywhere as long as what you're doing gets you out of breath," it adds.

Originally posted here:
Type 2 diabetes symptoms: Do you experience 'dark adaption'? It could be a warning sign - Express

Notice: This Content doesnt contain all the Information of the Report please fill the form (via link) and get all interesting information just one click in PDF with the latest update with chart and Table of Content

The report offers a systematic presentation of the existing trends, growth opportunities, market dynamics that are expected to shape the growth of the Peripheral Neuropathy Treatment Market. The various research methods and tools were involved in the market analysis, to uncover crucial information about the market such as current & future trends, opportunities, business strategies and more, which in turn will aid the business decision-makers to make the right decision in the future.

This Report Covers Leading Companies Associated in Worldwide Peripheral Neuropathy Treatment Market: Abbott, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc., Lupin Limited, Merck and Co. Inc., Novartis AG, Pfizer Inc., Dr. Reddys Laboratories, Mylan NV, Johnson & Johnson Services Inc., and Teva Pharmaceutical Industries Ltd. among others.

We Do Offer Sample of this report. Kindly go through the following information in order to access the report.

Note- This report sample includes:

Brief Introduction to the research report. Table of Contents (Scope covered as a part of the study) Top players in the market Research framework (Structure Of The Report) Research methodology adopted by Coherent Market Insights

Get Sample Copy Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/4363

The report begins with a brief introduction and market overview of the Peripheral Neuropathy Treatment industry followed by its market scope and size. Next, the report provides an overview of market segmentation such as type, application, and region. The drivers, limitations, and opportunities for the market are also listed along with current trends and policies in the industry.

Regions included:

The PDF Research only provides a Table of Contents (ToC), the scope of the report and research framework of the report.

Get Free PDF Brochure Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/4363

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of Peripheral Neuropathy Treatment

o The micro-level analysis is conducted based on its product types, end-user applications, and geographies

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Peripheral Neuropathy Treatment market

The research study can answer the following Key questions:

Table of Contents

Report Overview: It includes the Peripheral Neuropathy Treatment market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Peripheral Neuropathy Treatment market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Peripheral Neuropathy Treatment market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the Peripheral Neuropathy Treatment market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

LIMITED TIME OFFER Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/4363

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, LATAM, West Europe, MENA Countries, Southeast Asia or the Asia Pacific.

Read the original:
Peripheral Neuropathy Treatment Market Research Report Presents A Thorough Study On The Overall Market By Application NeighborWebSJ - NeighborWebSJ

Diabetic Peripheral Neuropathy Treatment Market In-depth Analysis 2021-2026

The report include a thorough study of the global Diabetic Peripheral Neuropathy TreatmentMarket. It has successfully pointed out the key factors that have substantial impact on theDiabetic Peripheral Neuropathy Treatment Market . This report is a result of a well-planned research methodology. The methodology employed both primary and secondary research tools.These tools aid the researchers to gather authentic data and arrive at a definite conclusion. The prevailing competitors in the global Diabetic Peripheral Neuropathy TreatmentMarket has also been pictured in the report, offering an opportunity to theDiabetic Peripheral Neuropathy Treatment Market players to measuring system their performance.

Millions of people across the world were infected with the novel coronavirus, because of while several food prohibitions and work orders stoppages were implemented. Other than the medical supplies and life support product industries, all other major industries have been severely impacted. In fact, Diabetic Peripheral Neuropathy Treatment major industries have been affected because of the COVID-19 outbreak.

Get Access to Report Sample: https://garnerinsights.com/Global-Diabetic-Peripheral-Neuropathy-Treatment-Market-Trends-By-Regional-Analysis-America-Europe-Asia-Pacific-and-Middle-EastAfrica-Growth-Opportunity-and-Industry-Forecast-2021-2026#request-sample

Major Key Players of the Diabetic Peripheral Neuropathy Treatment Market are: Achelios Therapeutics Inc, Celgene Corp, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals Inc, KPI Therapeutics Inc, Medifron DBT Co Ltd, Mitsubishi Tanabe Pharma Corp, Novaremed Ltd, Reata Pharmaceuticals Inc, Relief Therapeutics Holding AG, ViroMed Co Ltd,

Major Types of Diabetic Peripheral Neuropathy Treatment covered are: Antimunocel, ASP-8477, BNV-222, Capsaicin, CBX-129801, Others

Major Applications of Diabetic Peripheral Neuropathy Treatment covered are: Hospital, Clinic, Others

The report has been prepared after studying the different parameters ruling the global Diabetic Peripheral Neuropathy TreatmentMarket and the forecast period has been estimated from2021-2026. The forecast period is the time period when the key factors and parameters will help the market to flourish significantly. The estimated value of the market has been represented through a CAGR percentage. Additionally, the report represents the approximate revenue that can be generated over the forecast period. However, the report has also outlined the factors that can slowdown the growth of the global Diabetic Peripheral Neuropathy TreatmentMarket.

Get Discount on this Report:https://garnerinsights.com/Global-Diabetic-Peripheral-Neuropathy-Treatment-Market-Trends-By-Regional-Analysis-America-Europe-Asia-Pacific-and-Middle-EastAfrica-Growth-Opportunity-and-Industry-Forecast-2021-2026#discount

Key Drivers

The report includes the key driving forces prevailing in the global Diabetic Peripheral Neuropathy TreatmentMarket. This part of the report has been studied keeping in mind the political, economic, social, technological, geographical, and cultural scenario of the global Diabetic Peripheral Neuropathy TreatmentMarket. These factors can be projected to have their individual effects on the market, or they can have interconnected impacts. Besides, subtle change in the time framewithin which these factors are functioning might have ripple effects on the global Diabetic Peripheral Neuropathy TreatmentMarket.

Regional

Global Diabetic Peripheral Neuropathy TreatmentMarket has been segmented into Europe, the Americas, Asia Pacific, and the Middle East & Africa. This part of the report provides an exhaustive view of the regional scope existing in the global Diabetic Peripheral Neuropathy TreatmentMarket. The trends and preferences dominating each region has a direct impact on the industries. The report tries to exploit the trends and preferences prevailing in a region to offer the users with a clear picture of the business potential existing in that region.

Research Methodology

The primary research procedure conducted to arrive at the results includes panel of face to face interviews with industry experts and consumers. The secondary research procedure includes an intricate study of the scholarly journals and reports available online.

View Full Report Description with TOC:https://garnerinsights.com/Global-Diabetic-Peripheral-Neuropathy-Treatment-Market-Trends-By-Regional-Analysis-America-Europe-Asia-Pacific-and-Middle-EastAfrica-Growth-Opportunity-and-Industry-Forecast-2021-2026

About Garner Insights:Garner Insights is a Market Intelligence and consulting firm with an all-inclusive experience and vast knowledge of the market research industry. Our vast storage of research reports across various categories, gives you a complete view of the ever changing and developing trends and current topics worldwide. Our constant endeavor is to keep on improving our storage information by providing rich market reports and constantly improving them.

Contact Us:Mr. Kevin ThomasDirect:+1 513 549 5911 (US)+44 203 318 2846 (UK)Email:sales@garnerinsights.com

Follow this link:
Diabetic Peripheral Neuropathy Treatment Market Trend, Segmentation and Opportunities Forecast To 2026 - The Courier

Data Bridge Market Reports Present Diabetic Neuropathy Market new report to its research database. The report first introduces the market basics like definitions, classifications, applications, and industry chain overview, and then industry policies and plans, product specifications, manufacturing processes, cost structures, and so on. The report highlights the change in the market which is taking place due to the moves of key players and brands such as product launches, joint ventures, mergers, and acquisitions that in turn change the view of the global face of the industry. According to the report, the global market is anticipated to witness a relatively higher growth rate during the forecast period. This Diabetic Neuropathy Market report also evaluates the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors, and Porters Five Forces Analysis.

This market research report surely provides productive ideas with which product can be made more effective and striking in the competitive market. The market data analyzed in this Diabetic Neuropathy Market report makes you achieve the business goal and objective in the predetermined time frame. This report deals with the precise study of the industry which explains the market definition, classifications, applications, engagements, and global industry trends. The Global Diabetic Neuropathy Market research report displays important product developments and tracks recent acquisitions, mergers, and research in the industry by the key players

Diabetic Neuropathy Market Insight:

The diabetic neuropathy market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a CAGR of 4.90% in the above-mentioned research forecast period. The rising prevalence of diabetes disorders worldwide and emerging markets is the factor responsible for the growth of the diabetic neuropathy market.

Get Free Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) at:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-diabetic-neuropathy-market

This Free report sample includes:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Prominent Key Players Covered in the report:

Pfizer Inc., Janssen Pharmaceuticals, Inc., Eli Lilly and Company, ACTAVIS, Cephalon, Inc., MEDA Pharma GmbH & Co. KG, GlaxoSmithKline plc, NeuroMetrix, Inc

Key Pointers Covered in the Diabetic Neuropathy Market Industry Trends and Forecast

TheDiabetic Neuropathy marketreport provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Diabetic Neuropathy market.

Major Regions as Follows:

Get Table Of Contents of This Premium Research For Free @https://www.databridgemarketresearch.com/toc/?dbmr=global-diabetic-neuropathy-market

The report includes accurately drawn facts and figures, along with graphical representations of vital market data. The research report sheds light on the emerging market segments and significant factors influencing the growth of the industry to help investors capitalize on the existing growth opportunities.

How insights and forecast from the reports could benefit you:

Why choose us:

Table Of Contents: Diabetic Neuropathy Market

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Part 07:Five Forces Analysis

Part 08:Market Segmentation

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Part 16:Appendix

Make an Inquiry of theDiabetic Neuropathy Market Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-diabetic-neuropathy-market

To summarize:

The global Diabetic Neuropathy market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

We are grateful to you for reading our report. If you wish to find more details of the report or want customization, contact us. You can get a detail of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

More here:
Diabetic Neuropathy Market To Register Phenomenal Growth in the Period of 2027 - The Courier

THURSDAY, Feb. 4, 2021 (HealthDay News) -- Social deprivation is associated with diabetes-related foot disease (DFD) in patients newly diagnosed with type 2 diabetes, according to a study published online Jan. 22 in Diabetes Care.

Jenny Riley, from University of Birmingham in the United Kingdom, and colleagues investigated the relationship between social deprivation and incident DFD in newly diagnosed patients with type 2 diabetes. The analysis included 150,265 patients.

The researchers found that over 3.27 years, DFD developed in 12.1 percent of the study population. Using the Townsend deprivation index, individuals in the most deprived quintile had an increased risk for DFD versus those in the least deprived quintile (adjusted hazard ratio [aHR], 1.22) when adjusting for sex, age at type 2 diabetes diagnosis, ethnicity, smoking, body mass index, hemoglobin A1c, cardiovascular disease, hypertension, retinopathy, estimated glomerular filtration rate, insulin, glucose/lipid-lowering medication, and baseline foot risk. Additionally, compared with those in the least deprived quintile, those in the most deprived quintile had a higher risk for peripheral neuropathy (aHR, 1.18), foot ulcer (aHR, 1.44), peripheral vascular disease (aHR, 1.40), lower-limb amputation (aHR, 1.75), and gangrene (aHR, 8.49).

"Considering the high individual and economic burdens of DFD, strategies targeting patients in socially deprived areas are needed to reduce health inequalities," the authors write.

Abstract/Full Text (subscription or payment may be required)

See the rest here:
Deprivation Tied to Foot Disease With New Type 2 Diabetes - HealthDay News

Chemotherapy Induced Peripheral Neuropathy Treatment Market Data and Acquisition Research Study with Trends and Opportunities 2019-2024,The study of Chemotherapy Induced Peripheral Neuropathy Treatment market is a compilation of the market of Chemotherapy Induced Peripheral Neuropathy Treatment broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Chemotherapy Induced Peripheral Neuropathy Treatment industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Chemotherapy Induced Peripheral Neuropathy Treatment industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Download PDF Sample of Chemotherapy Induced Peripheral Neuropathy Treatment Market report @ https://hongchunresearch.com/request-a-sample/117227

Key players in the global Chemotherapy Induced Peripheral Neuropathy Treatment market covered in Chapter 4:,DermaXon,Solasia Pharma,PledPharma,Apexian Pharma,WinSanTor,Nemus Bioscience,Regenacy Pharmaceuticals,Asahi Kasei Pharma,Kineta,MAKScientific,PeriphaGen,Metys Pharmaceuticals,Immune Pharmaceuticals,Aptinyx,Krenitsky Pharmaceuticals,Sova Pharmaceuticals

In Chapter 11 and 13.3, on the basis of types, the Chemotherapy Induced Peripheral Neuropathy Treatment market from 2015 to 2026 is primarily split into:,Calcium Channel 2-delta Ligands,Antidepressants,Opioids,Others

In Chapter 12 and 13.4, on the basis of applications, the Chemotherapy Induced Peripheral Neuropathy Treatment market from 2015 to 2026 covers:,Platinum Agents,Taxanes,Vinca Alkaloids,Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:,North America (Covered in Chapter 6 and 13),United States,Canada,Mexico,Europe (Covered in Chapter 7 and 13),Germany,UK,France,Italy,Spain,Russia,Others,Asia-Pacific (Covered in Chapter 8 and 13),China,Japan,South Korea,Australia,India,Southeast Asia,Others,Middle East and Africa (Covered in Chapter 9 and 13),Saudi Arabia,UAE,Egypt,Nigeria,South Africa,Others,South America (Covered in Chapter 10 and 13),Brazil,Argentina,Columbia,Chile,Others,Regional scope can be customized

For a global outreach, the Chemotherapy Induced Peripheral Neuropathy Treatment study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:,Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitions,Revenue, cost price, capacity & utilizations, import/export rates and market share,Forecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

Brief about Chemotherapy Induced Peripheral Neuropathy Treatment Market Report with [emailprotected]https://hongchunresearch.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-market-size-2020-117227

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Chemotherapy Induced Peripheral Neuropathy Treatment Market

Chapter Four: Players Profiles

Chapter Five: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis by Regions

Chapter Six: North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis by Countries

Chapter Seven: Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis by Countries

Chapter Eight: Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis by Countries

Chapter Nine: Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis by Countries

Chapter Ten: South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis by Countries

Chapter Eleven: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment by Types

Chapter Twelve: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment by Applications 12.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Applications (2015-2020) 12.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Applications (2015-2020) 12.2 Platinum Agents Sales, Revenue and Growth Rate (2015-2020) 12.3 Taxanes Sales, Revenue and Growth Rate (2015-2020) 12.4 Vinca Alkaloids Sales, Revenue and Growth Rate (2015-2020) 12.5 Others Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/117227

Make Enquiry and Get Flat 40% Discount on This Report

List of tablesList of Tables and Figures Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Type (2020-2026) Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type in 2019 & 2026 Figure Calcium Channel 2-delta Ligands Features Figure Antidepressants Features Figure Opioids Features Figure Others Features Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth by Application (2020-2026) Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application in 2019 & 2026 Figure Platinum Agents Description Figure Taxanes Description Figure Vinca Alkaloids Description Figure Others Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Chemotherapy Induced Peripheral Neuropathy Treatment Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Chemotherapy Induced Peripheral Neuropathy Treatment Figure Production Process of Chemotherapy Induced Peripheral Neuropathy Treatment Figure Manufacturing Cost Structure of Chemotherapy Induced Peripheral Neuropathy Treatment Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table DermaXon Profile Table DermaXon Production, Value, Price, Gross Margin 2015-2020 Table Solasia Pharma Profile Table Solasia Pharma Production, Value, Price, Gross Margin 2015-2020 Table PledPharma Profile Table PledPharma Production, Value, Price, Gross Margin 2015-2020 Table Apexian Pharma Profile Table Apexian Pharma Production, Value, Price, Gross Margin 2015-2020 Table WinSanTor Profile Table WinSanTor Production, Value, Price, Gross Margin 2015-2020 Table Nemus Bioscience Profile Table Nemus Bioscience Production, Value, Price, Gross Margin 2015-2020 Table Regenacy Pharmaceuticals Profile Table Regenacy Pharmaceuticals Production, Value, Price, Gross Margin 2015-2020 Table Asahi Kasei Pharma Profile Table Asahi Kasei Pharma Production, Value, Price, Gross Margin 2015-2020 Table Kineta Profile Table Kineta Production, Value, Price, Gross Margin 2015-2020 Table MAKScientific Profile Table MAKScientific Production, Value, Price, Gross Margin 2015-2020 Table PeriphaGen Profile Table PeriphaGen Production, Value, Price, Gross Margin 2015-2020 Table Metys Pharmaceuticals Profile Table Metys Pharmaceuticals Production, Value, Price, Gross Margin 2015-2020 Table Immune Pharmaceuticals Profile Table Immune Pharmaceuticals Production, Value, Price, Gross Margin 2015-2020 Table Aptinyx Profile Table Aptinyx Production, Value, Price, Gross Margin 2015-2020 Table Krenitsky Pharmaceuticals Profile Table Krenitsky Pharmaceuticals Production, Value, Price, Gross Margin 2015-2020 Table Sova Pharmaceuticals Profile Table Sova Pharmaceuticals Production, Value, Price, Gross Margin 2015-2020 Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue ($) and Growth (2015-2020) Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Regions (2015-2020) Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Regions (2015-2020) Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue ($) by Regions (2015-2020) Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions (2015-2020) Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions in 2015 Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions in 2019 Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue ($) and Growth (2015-2020) Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries (2015-2020) Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries (2015-2020) Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries in 2015 Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries in 2019 Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue ($) by Countries (2015-2020) Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2015-2020) Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries in 2015 Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries in 2019 Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth (2015-2020) Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue ($) Growth (2015-2020) Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries (2015-2020) Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries (2015-2020) Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries in 2015 Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries in 2019 Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue ($) by Countries (2015-2020) Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2015-2020) Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries in 2015 Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries in 2019 Figure Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure UK Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure France Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Spain Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue ($) and Growth (2015-2020) Table Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries (2015-2020) Table Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries in 2015 Figure Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Countries in 2019 Table Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue ($) by Countries (2015-2020) Table Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries in 2015 Figure Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Countries in 2019 Figure China Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Australia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure India Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2015-2020) Figure Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Go here to see the original:
Chemotherapy Induced Peripheral Neuropathy Treatment Market Size 2020 Analysis By Industry Share, Emerging Demands, Growth Rate, Recent & Future...

A recent report added by Market Study Report, LLC, on ' Diabetic Neuropathy Treatment Market' provides a detailed analysis on the industry size, revenue forecasts and geographical landscape pertaining to this business space. Additionally, the report highlights primary obstacles and latest growth trends accepted by key players that form a part of the competitive spectrum of this business.

.

Request a sample Report of Diabetic Neuropathy Treatment Market at:https://www.marketstudyreport.com/request-a-sample/2486060?utm_source=algosonline.com&utm_medium=SK

This report also researches and evaluates the impact of Covid-19 outbreak on the Diabetic Neuropathy Treatment industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Diabetic Neuropathy Treatment and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

The Diabetic Neuropathy Treatment research report is an all-inclusive evaluation of this industry sphere. The report estimates market share and growth rate of the industry vertical during the forecast period. It also explicates all the important facets of Diabetic Neuropathy Treatment market such as estimated revenue, industry size, and total sales generated. Furthermore, the study provides data about the industry segments as well as the growth drivers that will positively impact the profitability graph over the estimated timeframe.

The Diabetic Neuropathy Treatment market with respect to the regional analysis:

Ask for Discount on Diabetic Neuropathy Treatment Market Report at:https://www.marketstudyreport.com/check-for-discount/2486060?utm_source=algosonline.com&utm_medium=SK

Additional highlights about Diabetic Neuropathy Treatment market from the report:

Report Objectives:

The research study can answer the following Key questions:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-diabetic-neuropathy-treatment-market-2020-by-company-regions-type-and-application-forecast-to-2025

Related Reports:

1. Global Syndromic Multiplex Diagnostic Market 2021 by Company, Regions, Type and Application, Forecast to 2026Read More: https://www.marketstudyreport.com/reports/global-syndromic-multiplex-diagnostic-market-2021-by-company-regions-type-and-application-forecast-to-2026

2. Global Precision Cancer Imaging Market 2021 by Company, Regions, Type and Application, Forecast to 2026Read More: https://www.marketstudyreport.com/reports/global-precision-cancer-imaging-market-2021-by-company-regions-type-and-application-forecast-to-2026

Related Report : https://www.marketwatch.com/press-release/testing-and-analysis-services-market-analysis-to-2027--key-drivers-challenges-and-trends-2021-01-29

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read the original:
Global Diabetic Neuropathy Treatment Market Growth, Size, Analysis, Outlook by 2020 - Trends, Opportunities and Forecast to 2025 - AlgosOnline

This transcript has been edited for clarity.

Matthew F. Watto, MD: I am Dr Frank Watto, and that is Dr Stuart K. Brigham. With us is our good friend, Dr Paul Nelson Williams.

Paul N. Williams, MD: This time around we are going to talk about our episode with Dr Jorge Castillo on monoclonal gammopathy of undetermined significance (MGUS) and interpreting the notorious serum protein electrophoresis (SPEP) test. We'll start with Stuart and find out what takeaway points he gleaned from this episode.

Stuart K. Brigham, MD: My takeaway is a way to understand SPEP using the "shaka sign."

You have the albumin, alpha 1, alpha 2, beta, and gamma region. What you should see is the smooth appearance of the gamma region, but if you have a gammopathy in the gamma region, you'll see a spike. That's why it's called M-spike. If you have a polyclonal gammopathy, it shifts the albumin:globulin ratio.

To springboard on that, what I took away from the episode is the importance of immunofixation in identifying that protein in the gamma region and how to interpret it.

Watto: The SPEP tells you whether there is an M-spike, meaning that some kind of monoclonal protein is being produced. Immunofixation tells you whether it's IgG, IgM, IgA. Is it a light chain? It basically tells you the specificity.

One of the biggest points for me from this episode was the "big three" in MGUS. MGUS is where you have a monoclonal protein, and MGUS doesn't often progress to anything. About 1% a year progresses to multiple myeloma. An IgM type of MGUS progresses a little more, maybe 1.5%.

The big three are multiple myeloma, amyloidosis, and Waldenstrom's macroglobulinemia. The illness scripts for those are relatively simple and really good to just keep in your back pocket.

For multiple myeloma, think CRAB: C (hypercalcemia); R (renal abnormality; usually elevated creatinine); A (anemia); and B (bone lesions). That's why we get a bone survey looking for lytic lesions.

Amyloidosis can cause cardiac abnormalities, macroglossia, nephrotic syndrome, and a type of neuropathy. Dr Castillo pointed out that patients can have both a motor and sensory neuropathy, and associated muscle wasting, which is different from the typical diabetic neuropathy.

Finally there is Waldenstrom's macroglobulinemia, which is really more of a lymphoma. Waldenstrom's has anemia as well as hyperviscosity syndrome. I had no idea what that meant.

Williams: This was a really helpful illness script, because Waldenstrom's was something that I knew for the boards at one point but I've probably forgotten about and don't think about much. Dr Castillo made the point that you could potentially save a patient's life if you have the right threshold of suspicion.

In terms of the hyperviscosity seen in Waldenstrom's, you have the epistaxis but you also have symptoms that should tip you off, including persistent headache and blurred vision that doesn't correct with glasses. There are all sorts of characteristic findings on fundoscopic examination.

This can get somewhat confusing, so don't fear referral. In amyloidosis, if you have the pathologic tissue diagnosis, congratulations; but if you don't, it doesn't mean the patient doesn't have it. If you aren't sure what to do, this is a great time to call on your friendly neighborhood hematologist. Even MGUS, which is recognized as benign, can progress, so they have to monitor and know what fancy-pants labs to order. It's okay to be confused because we all are. I was certainly helped by this episode. Just don't be afraid to call hematology if you aren't sure what to do.

Watto: One more thing about Waldenstrom's that I'm not sure I mentioned earlier: The neuropathy associated with it is more of a peripheral neuropathy that tends to involve the hands and the feet. If someone has a symmetrical distal neuropathy and it doesn't quite make sense because they don't have diabetes, this might be something to think about. It's different from amyloidosis because there's no motor involvement with this one.

This was a really complicated topic and our guest did a great job of explaining it. To hear the full episode, go to #247: SPEP It Up, or find The Curbsiders' podcasts on iTunes.

You can read our show notes on that episode and join our mailing list. Thank you for watching.

The Curbsiders are a national network of students, residents, and clinician educators from across the country, representing 15 different institutions. They "curbside" experts to deconstruct various topics in the world of medicine to provide listeners with clinical pearls, practice-changing knowledge, and bad puns. Learn more about their contributors and follow them on Twitter.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Follow this link:
MGUS, SPEP, and the Shaka Sign - Medscape

Chemotherapy Induced Peripheral Neuropathy Treatment Marketresearch report is the new statistical data source added byA2Z Market Research.

Chemotherapy Induced Peripheral Neuropathy Treatment Market is growing at a High CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Chemotherapy Induced Peripheral Neuropathy Treatment Marketresearch is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=383624

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

DermaXon, Solasia Pharma, PledPharma, Apexian Pharma, WinSanTor, Nemus Bioscience, Regenacy Pharmaceuticals, Asahi Kasei Pharma, Kineta, MAKScientific, PeriphaGen, Metys Pharmaceuticals, Immune Pharmaceuticals, Aptinyx, Krenitsky Pharmaceuticals, Sova Pharmaceuticals.

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Chemotherapy Induced Peripheral Neuropathy Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Chemotherapy Induced Peripheral Neuropathy Treatment markets trajectory between forecast periods.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation:

Market Segmentation: By Type

Calcium Channel 2-delta LigandsAntidepressantsOpioidsOthers

Market Segmentation: By Application

Platinum AgentsTaxanesVinca AlkaloidsOthers

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=383624

Regions Covered in the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2021:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Chemotherapy Induced Peripheral Neuropathy Treatment market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Chemotherapy Induced Peripheral Neuropathy Treatment market.

Table of Contents

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Research Report 2021 2027

Chapter 1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=383624

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

https://murphyshockeylaw.net/

Read the original:
Impact of COVID-19 on Chemotherapy Induced Peripheral Neuropathy Treatment Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 |...

DataIntelo, the fastest growing market research company, has published a report on the Neuropathy Pain Treatment market. This market report provides a holistic scope of the market which includes future supply and demand scenarios, changing market trends, high growth opportunities, and in-depth analysis of the future market prospects. The report covers the competitive data analysis of the emerging and prominent players of the market. Along with this, it provides comprehensive data analysis on the risk factors, challenges, and possible new market avenues.

The report has been prepared with the help of a robust research methodology to cover the market in a detailed manner. To publish a top-notch Neuropathy Pain Treatment Market report, the market report has undergone extensive primary and secondary research. The dedicated research team conducted interviews with the delegated industry experts to lay out a complete overview of the market. This market research report covers the product pricing factors, revenue drivers, and growth. Furthermore, it can possibly assist the new entrants and even the existing industry players to tailor a strategic business strategy for their products.

You can buy the sample report @ https://dataintelo.com/request-sample/?reportId=43829

Impact of COVID-19 to the Neuropathy Pain Treatment Report

This coronavirus outbreak has led various industry players to change business strategies and innovate their products. Moreover, it has created lucrative opportunities and few fallbacks that has revamped the overall industry. This report has integrated the data influenced by the COVID-19 effect and provided granular analysis on what market segments would play a crucial role in the growth of the Neuropathy Pain Treatment market. It also includes insights into the successful strategies implemented by the leading players to stay ahead in the competition.

The market research team has been closely monitoring the market since 2015 and has covered the wide spectrum of the market to provide insightful data for the forecast period 2020-2027. DataIntelo has provided crucial data in a graphical representation with the help of tables, bar graphs, pie charts, histograms, and infographics. To give a detailed analysis of the market, the market segments have been fragmented into sub-segments. The segments drivers, challenges, and restraints are also considered which is vital for the market growth. Besides this, it also covers the impacts of government regulation policies and regulations on the market.

You can buy the complete report @ https://dataintelo.com/checkout/?reportId=43829

5 Reasons to Choose DataIntelo to Buy This Market Report

Market Segmentation Covered in the Report

By Product Type

Calcium Channel Alpha 2-delta LigandsSerotonin-norepinephrine Reuptake InhibitorsOthers

By Applications

Retail PharmaciesHospitalsOthers

By Regional Analysis

Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

Competitive Landscape

The major players of the Neuropathy Pain Treatment market are:

DepomedEli LillyEndo InternationalPfizerAllodynic TherapeuticsArbor Pharmaceuticals

*Note: Additional companies detailed analysis can be added in the report.

If you have any questions on this report, please reach out to us @ https://dataintelo.com/enquiry-before-buying/?reportId=43829

Table of Content of the Report

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Neuropathy Pain Treatment Market Overview

Global Neuropathy Pain Treatment Market Analysis and Forecast by Type

Global Neuropathy Pain Treatment Market Analysis and Forecast by Application

Global Neuropathy Pain Treatment Market Analysis and Forecast by Sales Channel

Global Neuropathy Pain Treatment Market Analysis and Forecast by Region

North America Neuropathy Pain Treatment Market Analysis and Forecast

Latin America Neuropathy Pain Treatment Market Analysis and Forecast

Europe Neuropathy Pain Treatment Market Analysis and Forecast

Asia Pacific Neuropathy Pain Treatment Market Analysis and Forecast

Asia Pacific Neuropathy Pain Treatment Market Size and Volume Forecast by Application

Middle East & Africa Neuropathy Pain Treatment Market Analysis and Forecast

Competition Landscape

About the company

DataIntelo is the largest aggregator of the market research report in the industry with more than 800 global clients. The company has extensively invested in the research analysts training and programs to keep the analyst tapped with the best industry standards and provide the clients with the utmost experience. Our dedicated team has been collaborating with industry experts to give out the precise data and figures related to the industry. It conducts primary research, secondary research, and consumer surveys to provide an in-depth analysis of the market. The market research firm has worked in several business verticals and has been successful to earn high credentials over time.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Original post:
Neuropathy Pain Treatment Market Analysis With Key Players, Applications, Trends And Forecasts To 2027 Iran Independent News Service - Iran...

Patients with advanced melanoma who had previously not respondedto immunotherapy showed a response after treatment with fecal transplants.

The material for the fecal transplants was obtained from patients who were experiencing a response to immunotherapy with the anti-PD-1 agent, pembrolizumab.

When the fecal transplants were given to the patients who had not responded, they "changed the gut microbiome and reprogrammed the tumor microenvironment to overcome resistance" to the immunotherapy, say researchers reporting a proof-of-concept study in Science.

The trial included 15 patients who received a fecal transplant and were then treated with pembrolizumab.

Six of the 15 showed a response.

One patient experienced a complete response; two experienced partial responses, one of which was ongoing in the absence of treatment after 2 years; and among three patients, disease was stable past 1 year.

One of the patients with stable disease again experienced disease progression after taking antibiotics for a soft tissue infection. Response resumed after a second transplant from their donor.

All six patients had been experiencing disease progression prior to the fecal transplant.

Dr Hassane Zarour

"The likelihood that the patients treated in this trial would spontaneously respond to a second administration of anti-PD-1 immunotherapy is very low, so any positive response should be attributable to the administration of fecal transplant," senior author Hassane Zarour, MD, a cancer immunologist and professor at the University of Pittsburg, Pittsburgh, Pennsylvania, said in a press release.

Dr Diwakar Davar

"Our findings show that a single FMT [fecal microbiota transplant] administered colonoscopically together with PD-1 blockade successfully colonized the gut of responders and reprogrammed the tumor microenvironment to overcome primary resistance to anti-PD-1," say investigators led by Diwakar Davar, MD, a medical oncologist and assistant professor at the University of Pittsburgh.

After transplant, the gut microbiome of the patients with restored responses was much like that of their donors. There was an increase in bacteria associated with CD8+ T-cell activation and with strong response to immune checkpoint inhibition, including bacteria of phyla Firmicutes and Actinobacteria. In these patients, levels of circulating and intertumoral interleukin-8, an immunosuppressive cytokine that interferes with PD-1 blockade. In addition, there were other cellular and biochemical changes that favored response.

"This is an excellent study," said Erez Baruch, MD, PhD, a researcher and internal medicine resident at the University of Texas Health Science Center, Houston, Texas, when asked for comment.

He led a similar but smaller study that was reported in Science in December 2020. In that study, 3 of 10 patients with metastatic melanoma whose conditions had stopped responding to checkpoint inhibition experienced a restored responseto nivolumab after fecal transplants from melanoma patients who had experienced complete and durable responses.

"The fact that two completely different cancer centers using different anti-PD-1 agents for reinduction reached the same clinical findings emphasizes the key role of the gut microbiota in immunotherapy. The two clinical trials validate each other," Baruch told Medscape Medical News.

The findings support the increasing realization in oncology that the gut microbiome affects the response to immunotherapy and that altering the microbiome might improve long-term response rates, which currently are not quite 40% in cases of advanced melanoma.

It's a hot topic, Baruch commented. Multiple clinical trials are in the works that will combine anti-PD-1 therapy with FMT for skin cancer and other malignancies. Investigators are looking for predictors of response and the particular bacterial species in play, in part so that they can be delivered in pill form some day.

"A lot of further lab work is required to understand exactly why some patients respond and why others do not. Samples collected in the trials will feed the lab work, and findings from the lab work will refine the trials. The circle will continue until the mechanisms of action are fully unmasked," Baruch said.

The material for the fecal transplants used in the pembrolizumab study came from seven donors, all of whom experienced response to pembrolizumab treatment for advanced melanoma. For four of the seven donors, the response was complete. The remaining three patients showed a partial response. The median progression-free survival (PFS) was 56 months.

The FMT success was unrelated to whether the material came from donors who had complete or partial responses, the researchers note.

In the trial, the patients who had not previously responded received pembrolizumab 200 mg at the time of transplant then every 3 weeks until progression or intolerable toxicity. Among the six responders, median PFS and overall survival was 14 months. A patient who had experienced a complete response died shortly after transplant from unrelated complications of spinal stenosis surgery. Among the entire cohort, median PFS was 3 months, and median overall survival was 7 months.

Adverse events were common but were of low grade except for grade 3 fatigue, which occurred in two patients, and peripheral motor neuropathy that required hospitalization, which occurred in one patient. The neuropathy resolved upon reintroduction of pembrolizumab.

The study was funded by the National Cancer Institute and by Merck, the maker of pembrolizumab. Davar, Zarour, and two other investigators have numerous ties to industry, among them research and/or consulting relationships with Merck and Bristol-Myers Squibb, maker of nivolumab. Baruch has disclosed no relevant financial relationships.

Science. Published online February 5, 2021. Abstract

M. Alexander Otto is a physician assistant with a masters degree in medical science, and an award-winning medical journalist who has worked for several major news outlets before joining Medscape, including McClatchy and Bloomberg. He is an MIT Knight Science Journalism fellow. Email: aotto@mdedge.com.

For more from Medscape Oncology, join us on Twitter and Facebook.

Originally posted here:
Fecal Transplant Overcomes Resistance to Immunotherapy - Medscape